On April 30, Innovent Biologics reported Q1 2026 results, with total product revenue exceeding RMB 3.8 billion, representing growth of over 50% year-on-year and underscoring the continued execution of its “dual-engine” growth strategy.

The company’s oncology franchise continues to strengthen its leading position, with five tyrosine kinase inhibitors (TKIs) recently added to China’s National Reimbursement Drug List (NRDL), driving rapid volume expansion. Meanwhile, its non-oncology portfolio has emerged as a key growth driver, led by strong performance from key products including mazdutide injection (Xinermei®), tolecisumab injection (Xinbiluo®), and tagitanercept N01 injection (Xinbimin®).

As of today, Innovent Biologics has 18 approved products in its commercial portfolio, reflecting its expanding presence across both oncology and broader therapeutic areas.